What is Zacks Research’s Forecast for Amgen FY2025 Earnings?

Amgen Inc. (NASDAQ:AMGN) – Analysts at Zacks Research lifted their FY2025 earnings per share estimates for shares of Amgen in a research report issued on Thursday, May 22nd. Zacks Research analyst R. Department now anticipates that the medical research company will post earnings per share of $20.66 for the year, up from their previous forecast of $20.16. The consensus estimate for Amgen’s current full-year earnings is $20.62 per share. Zacks Research also issued estimates for Amgen’s Q1 2027 earnings at $4.94 EPS and FY2027 earnings at $21.50 EPS.

Several other equities analysts have also recently issued reports on AMGN. Wall Street Zen upgraded Amgen from a “buy” rating to a “strong-buy” rating in a research report on Sunday, May 18th. Wells Fargo & Company reiterated an “equal weight” rating on shares of Amgen in a research report on Wednesday, February 5th. Bank of America lifted their price target on Amgen from $275.00 to $294.00 and gave the company an “underperform” rating in a research report on Wednesday, March 5th. Royal Bank of Canada lowered their price target on Amgen from $324.00 to $320.00 and set an “outperform” rating on the stock in a research report on Friday, May 2nd. Finally, Morgan Stanley reissued an “equal weight” rating on shares of Amgen in a research note on Friday, May 2nd. Two analysts have rated the stock with a sell rating, twelve have issued a hold rating, nine have issued a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $309.22.

Amgen Stock Down 0.1%

Shares of AMGN stock opened at $271.66 on Friday. Amgen has a 1 year low of $253.30 and a 1 year high of $346.85. The stock has a market cap of $146.07 billion, a PE ratio of 35.98, a price-to-earnings-growth ratio of 2.63 and a beta of 0.51. The business’s fifty day moving average is $286.82 and its 200-day moving average is $286.72. The company has a debt-to-equity ratio of 9.62, a quick ratio of 0.95 and a current ratio of 1.26.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Thursday, May 1st. The medical research company reported $4.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.18 by $0.72. Amgen had a return on equity of 176.32% and a net margin of 12.24%. The company had revenue of $8.15 billion for the quarter, compared to analysts’ expectations of $8.05 billion. During the same period last year, the firm earned $3.96 EPS. The firm’s revenue for the quarter was up 9.4% on a year-over-year basis.

Institutional Trading of Amgen

Several hedge funds and other institutional investors have recently modified their holdings of AMGN. Mattson Financial Services LLC boosted its position in Amgen by 16.6% during the first quarter. Mattson Financial Services LLC now owns 3,247 shares of the medical research company’s stock valued at $1,012,000 after purchasing an additional 463 shares during the last quarter. WBI Investments LLC acquired a new stake in Amgen during the first quarter valued at $1,007,000. Westbourne Investments Inc. boosted its position in Amgen by 5.5% during the first quarter. Westbourne Investments Inc. now owns 1,925 shares of the medical research company’s stock valued at $600,000 after purchasing an additional 100 shares during the last quarter. Acadian Asset Management LLC boosted its position in Amgen by 174.3% during the first quarter. Acadian Asset Management LLC now owns 20,328 shares of the medical research company’s stock valued at $6,329,000 after purchasing an additional 12,918 shares during the last quarter. Finally, Geneos Wealth Management Inc. boosted its position in Amgen by 9.0% during the first quarter. Geneos Wealth Management Inc. now owns 8,065 shares of the medical research company’s stock valued at $2,513,000 after purchasing an additional 669 shares during the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Stockholders of record on Friday, May 16th will be given a $2.38 dividend. The ex-dividend date is Friday, May 16th. This represents a $9.52 annualized dividend and a dividend yield of 3.50%. Amgen’s dividend payout ratio (DPR) is presently 86.86%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.